Weekly Recap | Upstream Bio -0.72%, most brokers rate it buyWeekly Review·Oct 24, 2026 at 07:12 AMUPB-8.36%
Weekly Recap | Sellas Life Sciences +15.63%, consensus target well above spotWeekly Review·Oct 24, 2026 at 07:01 AMSLS+1.67%
Weekly Recap | Summit Therapeutics +5.74%, ivonescimab data stack upWeekly Review·Oct 24, 2026 at 07:00 AMSMMT-0.51%
Weekly Recap | Beigene +2.32%, Tevimbra combination survival data landsWeekly Review·Oct 24, 2026 at 06:49 AMONC-1.21%
Weekly Recap | Moderna -8.22%, sell-off after cancer vaccine dataWeekly Review·Oct 24, 2026 at 06:41 AMMRNA-1.25%MRNY-2.25%
Weekly Recap | Jasper Therapeutics +6.27%, consensus target above spotWeekly Review·Oct 24, 2026 at 06:41 AMJSPR+2.91%
Weekly Recap | Legend Biotech +4.27%, consensus target above spotWeekly Review·Oct 24, 2026 at 06:36 AMLEGN+1.96%
The Nasdaq Biotechnology Index closed up more than 1.4%. Among the constituent stocks, Cullinan Oncology LLC rose 36.54%, Relay Therapeutics Inc. rose 20.68%, GRAIL rose 18.81%, and Lyell Immunopharma rose 18.71%. Meanwhile, Anavex Life Sciences fell 5.52%, Neumora Therapeutics fell 7.30%, and Arcellx fell 16.89%Wallstreetcn·Nov 24, 2025 at 09:17 PMLYEL+0.11%CGEM-3.69%
